Liquidia (LQDA) Income from Continuing Operations (2020 - 2026)
Liquidia's (LQDA) quarterly Income from Continuing Operations came in at 52882000.0 in Q1 2026, up 237.83% year-on-year from 15653342.91 in Q1 2025, and up 263.33% quarter-over-quarter from 14555000.0 in Q4 2025.
Liquidia (LQDA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Liquidia's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 52882000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 237.83% year-over-year to 52882000.0 in Q1 2026; TTM through Mar 2026 was 186865000.0, a 23.86% increase from a year earlier, with the FY2025 full-year figure at 293685000.0, down 28.44% from the prior year.
- Income from Continuing Operations grew to 52882000.0 in Q1 2026 per LQDA's latest filing, from 14555000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 52882000.0 in Q1 2026 and bottomed at 149910000.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 31183000.0 (2023), against an average of 43945352.94.
- Across the five-year window, Income from Continuing Operations slumped 293.38% in 2024 and soared 237.83% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 6533000.0 in 2022, then sank by 229.66% to 21537000.0 in 2023, then slumped by 78.81% to 38510000.0 in 2024, then jumped by 137.8% to 14555000.0 in 2025, then soared by 263.33% to 52882000.0 in 2026.
- Per Business Quant, the three latest LQDA Income from Continuing Operations figures stand at 52882000.0 (Q1 2026), 14555000.0 (Q4 2025), and 149910000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | 52.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.88 Mn |
| Dec 31, 2025 | 14.56 Mn |
| Sep 30, 2025 | -149.91 Mn |
| Jun 30, 2025 | -104.39 Mn |
| Mar 31, 2025 | -38.37 Mn |
| Dec 31, 2024 | -38.51 Mn |
| Sep 30, 2024 | -75.21 Mn |
| Jun 30, 2024 | -93.32 Mn |
| Mar 31, 2024 | -121.96 Mn |
| Dec 31, 2023 | -21.54 Mn |
| Sep 30, 2023 | -31.18 Mn |
| Jun 30, 2023 | -53.03 Mn |
| Mar 31, 2023 | -31.00 Mn |
| Dec 31, 2022 | -6.53 Mn |
| Sep 30, 2022 | -19.38 Mn |
| Jun 30, 2022 | -14.35 Mn |
| Mar 31, 2022 | -15.82 Mn |
| Dec 31, 2021 | -11.56 Mn |
| Sep 30, 2021 | -13.74 Mn |
| Jun 30, 2021 | -7.96 Mn |